89. Lymphangioleiomyomatosis
38 clinical trials,   42 drugs   (DrugBank: 19 drugs),   26 drug target genes,   134 drug target pathways

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02737202
(ClinicalTrials.gov)
April 201631/3/2016Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisSafety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisPulmonary LymphangioleiomyomatosisDrug: saracatinibBaylor College of MedicineUniversity of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;University of South Florida;National Institutes of Health (NIH)Terminated18 Years65 YearsFemale28Phase 2United States
2NCT02116712
(ClinicalTrials.gov)
August 201415/4/2014The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)Pulmonary LymphangioleiomyomatosisDrug: SaracatinibTony EissaUniversity of Texas;University of CincinnatiCompleted18 Years65 YearsBoth9Phase 1United States